Ami Fadia
Stock Analyst at Needham
(4.59)
# 242
Out of 5,134 analysts
345
Total ratings
53.91%
Success rate
27.98%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $187 → $185 | $127.76 | +44.80% | 17 | Feb 12, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $460 → $510 | $328.04 | +55.47% | 17 | Feb 4, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $210 → $235 | $167.98 | +39.90% | 35 | Jan 12, 2026 | |
| GHRS GH Research | Maintains: Buy | $19 → $29 | $15.99 | +81.36% | 3 | Jan 6, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $154 → $169 | $183.30 | -7.80% | 18 | Dec 31, 2025 | |
| COGT Cogent Biosciences | Reiterates: Hold | n/a | $37.62 | - | 24 | Dec 8, 2025 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Buy | $42 | $36.92 | +13.76% | 39 | Nov 24, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Buy | $16 | $11.88 | +34.68% | 22 | Nov 24, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $66 → $72 | $100.61 | -28.44% | 27 | Nov 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $28 → $29 | $22.95 | +26.36% | 12 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $44 | $32.90 | +33.74% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $3.54 | +125.99% | 10 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.80 | +215.79% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $5.12 | +114.84% | 20 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $195.62 | - | 43 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $24.98 | +40.11% | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 | $5.23 | +454.49% | 21 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $320 | $15.64 | +1,946.04% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $22.74 | +229.82% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $0.26 | +8,682.20% | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $14.44 | +336.29% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $34.41 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.19 | +1,748.74% | 4 | Jan 3, 2018 |
Neurocrine Biosciences
Feb 12, 2026
Maintains: Buy
Price Target: $187 → $185
Current: $127.76
Upside: +44.80%
Praxis Precision Medicines
Feb 4, 2026
Maintains: Buy
Price Target: $460 → $510
Current: $328.04
Upside: +55.47%
Jazz Pharmaceuticals
Jan 12, 2026
Maintains: Buy
Price Target: $210 → $235
Current: $167.98
Upside: +39.90%
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $19 → $29
Current: $15.99
Upside: +81.36%
Axsome Therapeutics
Dec 31, 2025
Maintains: Buy
Price Target: $154 → $169
Current: $183.30
Upside: -7.80%
Cogent Biosciences
Dec 8, 2025
Reiterates: Hold
Price Target: n/a
Current: $37.62
Upside: -
Harmony Biosciences Holdings
Nov 24, 2025
Reiterates: Buy
Price Target: $42
Current: $36.92
Upside: +13.76%
Day One Biopharmaceuticals
Nov 24, 2025
Reiterates: Buy
Price Target: $16
Current: $11.88
Upside: +34.68%
Revolution Medicines
Nov 6, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $100.61
Upside: -28.44%
ACADIA Pharmaceuticals
Nov 6, 2025
Maintains: Buy
Price Target: $28 → $29
Current: $22.95
Upside: +26.36%
Oct 29, 2025
Maintains: Buy
Price Target: $43 → $44
Current: $32.90
Upside: +33.74%
Oct 28, 2025
Maintains: Buy
Price Target: $6 → $8
Current: $3.54
Upside: +125.99%
Oct 13, 2025
Initiates: Buy
Price Target: $12
Current: $3.80
Upside: +215.79%
Sep 30, 2025
Reiterates: Buy
Price Target: $11
Current: $5.12
Upside: +114.84%
Sep 24, 2025
Reiterates: Hold
Price Target: n/a
Current: $195.62
Upside: -
May 28, 2025
Initiates: Buy
Price Target: $35
Current: $24.98
Upside: +40.11%
May 2, 2025
Reiterates: Buy
Price Target: $29
Current: $5.23
Upside: +454.49%
Feb 1, 2021
Maintains: Outperform
Price Target: $240 → $320
Current: $15.64
Upside: +1,946.04%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $22.74
Upside: +229.82%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $0.26
Upside: +8,682.20%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $14.44
Upside: +336.29%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $34.41
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $1.19
Upside: +1,748.74%